Welcome to the Cruise Ship Dispatch, where you don’t have to worry about the hantavirus, ably covered this month by The Morning Dispatch, but you might be overwhelmed by our daily buffet of news coverage and analysis. Interested in President Donald Trump’s Beijing summit with Chinese dictator Xi Jinping? We’ve got that. Curious about Ukraine’s latest (somewhat surprising) advances on the battlefield against Russia? We’ve got that. Hungry for information about personnel and policy changes at the Food and Drug Administration? Yeah, we’ve got that. Time to set sail.
—David
Top Stories From the Dispatch Politics Team
Marty Makary’s exit from the Food and Drug Administration follows a tumultuous 13-month tenure as the country’s top drug regulator. The FDA had been on the rocks for months, beset by controversy and instability that the commissioner himself had often galvanized. A break with Trump on vaping product regulations appeared to be the proximate cause of Makary’s ouster. But a host of critics both inside and outside of the administration ultimately hastened the downfall of a leader installed on the strength of his résumé as an institutional skeptic.
The U.S. and Ukraine are negotiating a deal to work together on developing and building attack drones—in exchange for much-needed drone expertise, Ukraine earns much-needed money to fund its existential fight with Russia. The deal is a step in the right direction, even if it is focused on offensive drones rather than addressing the defensive interceptor capability gap that cost us the AWACS. But more than a tactical problem, this drone issue is a strategic and political one—and it is the predictable result of devaluing and burning the very alliances and relationships that could help us most.
One of the stranger facets of modern American economic discourse is the left-right agreement that gross domestic product (GDP) doesn’t matter—and, in fact, is something only a soulless, globalist might consider when crafting policy. Leftist academics have pushed “degrowth” for years, insisting that only a government-induced reduction in economic output can save the environment and ensure human flourishing. More recently, the populist right has adopted its own version of growth skepticism, arguing that free-market policies—especially more liberalized trade and immigration, but also various tax and deregulatory efforts—sacrifice communities, families, and culture for nothing more than a small boost in GDP. And both sides’ economic doomerism depends on dismissing decades of solid American GDP growth as tone-deaf, ivory tower, “line goes up” elitism.
After years of taunts, threats, and tariffs, amid a war in the Middle East and tense negotiations to end it, the year’s most watched summit is about to begin. This week, President Donald Trump was in Beijing for a three-day visit with Chinese leader Xi Jinping—the first time a U.S. president has traveled to the country since the pair met in November 2017, and potentially the first of four in-person meetings this year. While the leaders are the same, the relationship between their countries has changed dramatically in the eight years since that last meeting.
It has become commonplace to dismiss concerns about soaring government debt as much ado about nothing—a modern case of the boy who cried wolf. Indeed, voters have cycled through catastrophic warnings about runaway deficits as far back as the Reagan administration, the 1992 Ross Perot presidential campaign, the mid-1990s “Republican Revolution” in Congress, and the early-2010s Tea Party era. And yet, continually rising budget deficits have not brought a debt crisis.
Enjoying our Dispatch Politics Roundup? Consider forwarding this article to someone you know who likes independent, fact-based journalism.
Want to see more of The Dispatch in Google search?
Add Us as a Preferred Source








